Decision amending the Decision of 20 December 2021 authorising the import and use of the medicinal product LAGEVRIO for the treatment of COVID-19 The Minister of Health, having regard to the law of 25 March 1964 on the medicinal products, Article 6quater, § 1, paragraph 5; having regard to the law of 13 June 2021 laying down measures for the control of the COVID-19 pandemic and other urgent measures in the field of health care, Article 8 and 27, 1°, b); having regard to the royal decision of 14 December 2006 on medicinal products for human and veterinary use, Article 110, third paragraph; having regard to the Laws of 20 December 2021 authorising the import and use of the medicinal product LAGEVRIO for the treatment of COVID-19; having regard to the opinion of the Inspector of Finance on 7 February 2022; having regard to the laws of the Council of State, coordinated on 12 January 1973, § 1; having regard to the urgency which does not allow the opinion of the Section of the State within a period of five days for the treatment of this treatment and the current treatment of COVID-19Whereas the positive interim results of the clinical trials with the medicinal product LAGEVRIO consisting of 200 mg molnupiravir; whereas the positive scientific opinion of 19 November 2021 of the Committee for Medicinal Products for Human Use (CHMP), established by the European Medicines Agency (EMA) (EMA/719664/2021), in accordance with Article 5 (3) of Regulation (EC) No 726/2004 of 19 November 2021 for the early use of LAGEVRIO before the marketing authorisation has been granted, in the light of the rising rates of infections and deaths resulting from COVID-19 in the European Union; whereas the recommendations concerning the use, distribution, target population and monitoring of the safety, annexed to the same opinion of the CHMP; whereas the marketing authorisation of the medicinal product LAGEVRIO is already granted by the medicinal product LAGEVRIO in accordance with Article 5 (3) of Regulation (EC) No.Whereas LAGEVRIO can reduce the viral load and thus limit the size of the COVID-19 outbreak; whereas, therefore, the distribution of Lagevrio to the residential care centres and hospitals affected should be carried out in a manner as expeditious and efficient as possible; whereas the compulsory delivery via a hospital pharmacy, as regards the residential care centres, is too cumbersome and time-consuming, given that the majority of the residential care centres mentioned cooperate with an official pharmacy, and not with a hospital pharmacy; whereas the loss of time incurred in the search of a hospital pharmacy, which can be found to deliver the residential care centres, would mean that the outbreak could not be combated during this time, which could lead to unnecessary hospitalizations or deaths; whereas, therefore, provision should be made as soon as possible that a delivery can also be made through the official pharmacy; whereas this delivery via the official dispensaries should be carried out under strict conditions to be carried out in accordance with the higher conditions of hospital treatment and to the(b) the patients referred to in point (a) show symptoms of the COVID-19 disease;The following shall be substituted for the following: "3° By way of derogation from the conditions referred to in point 2°, the wholesaler designated by the Minister, who, on behalf of the Belgian State, manages the strategic stock of medicinal products, may also supply the medicinal product LAGEVRIO to a hospital pharmacy, if this is intended to be served to patients in a hospital, as referred to in Article 2 (1) of the Coordinated Law of 10 July 2008 on hospitals and other care establishments, in so far as there is an outbreak of COVID-19 at the time of prescription in the hospital. The provision under 5° shall be replaced as follows: "5° After the outbreak of COVID-19 in the residential centre or hospital, the coordinating doctor shall complete the report to them which Sciensano provides and which the report returns to Scensano.